Immunotherapy for breast cancer

预约门诊
打印

科室与专家门诊

妙佑医疗国际是美国规模最大、经验最丰富的医疗机构之一，在亚利桑那州、佛罗里达州和明尼苏达州都设有院区。我们的工作人员涉及数十种专业，通过齐心协力确保高品质治疗与成功康复。

有相关专长的科室

行此手术的医生

编辑搜索过滤条件
close

缩小搜索范围

  1. 查找姓氏以该字母开头的医生 A
  2. 未找到姓氏以该字母开头的医生 B
  3. 未找到姓氏以该字母开头的医生 C
  4. 未找到姓氏以该字母开头的医生 D
  5. 未找到姓氏以该字母开头的医生 E
  6. 未找到姓氏以该字母开头的医生 F
  7. 未找到姓氏以该字母开头的医生 G
  8. 未找到姓氏以该字母开头的医生 H
  9. 未找到姓氏以该字母开头的医生 I
  10. 未找到姓氏以该字母开头的医生 J
  11. 未找到姓氏以该字母开头的医生 K
  12. 未找到姓氏以该字母开头的医生 L
  13. 未找到姓氏以该字母开头的医生 M
  14. 未找到姓氏以该字母开头的医生 N
  15. 未找到姓氏以该字母开头的医生 O
  16. 未找到姓氏以该字母开头的医生 P
  17. 未找到姓氏以该字母开头的医生 Q
  18. 未找到姓氏以该字母开头的医生 R
  19. 未找到姓氏以该字母开头的医生 S
  20. 未找到姓氏以该字母开头的医生 T
  21. 未找到姓氏以该字母开头的医生 U
  22. 未找到姓氏以该字母开头的医生 V
  23. 未找到姓氏以该字母开头的医生 W
  24. 未找到姓氏以该字母开头的医生 X
  25. 未找到姓氏以该字母开头的医生 Y
  26. 未找到姓氏以该字母开头的医生 Z
重置所有过滤器

显示$起始范围 - $结束范围/源自可用$可用医生

  1. Karen S. Anderson, M.D., Ph.D.
    擅长领域：

    Immunotherapy for breast cancer, HPV infection, Breast cancer, Pancreatic cancer, Ovarian cancer

Research Profiles

编辑搜索过滤条件
close

缩小搜索范围

查看所有医生 • 所有位置

来自妙佑医疗国际员工

在 Mayo Clinic 治疗

申请预约
关于在 Mayo Clinic 治疗
Sept. 05, 2026
打印
  1. FDA approves sacituzumab govitecan-hziy as monotherapy and in combination with pembrolizumab for first-line treatment of triple-negative breast cancer. U.S. Food and Drug Administration. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line. Accessed Aug. 4, 2026.
  2. Immunotherapy for breast cancer. National Cancer Institute. https://www.cancer.gov/types/breast/treatment/immunotherapy. Accessed Aug. 4, 2026.
  3. Schmid P, et al. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. New England Journal of Medicine. 2024; doi:10.1056/NEJMoa2409932.
  4. Heater NK, et al. Current and future immunotherapy for breast cancer. Journal of Hematology & Oncology. 2024; doi:10.1186/s13045-024-01649-z.
  5. Immune checkpoint inhibitors. National Cancer Institute. https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/checkpoint-inhibitors. Accessed Aug. 4, 2026.
  6. Cortes J, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. New England Journal of Medicine. 2022; doi:10.1056/NEJMoa2202809.
  7. Raghavendra AS, et al. Breast cancer brain metastasis: A comprehensive review. JCO Oncology Practice. 2024; doi:10.1200/OP.23.00794.
  8. Villacampa G, et al. Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: A systematic review and meta-analysis. JAMA Oncology. 2024; doi:10.1001/jamaoncol.2024.3456.
  9. Verma S, et al. Immunotherapy and radiation therapy sequencing in breast cancer: A systematic review. International Journal of Radiation Oncology, Biology, Physics. 2024; doi:10.1016/j.ijrobp.2024.01.001.
  10. Madsen AMH, et al. Targeted treatment of metastatic triple-negative breast cancer: A systematic review. The Breast Journal. 2024; doi:10.1155/2024/9083055.
  11. Chemotherapy for breast cancer. National Cancer Institute. https://www.cancer.gov/types/breast/treatment/chemotherapy. Accessed Aug. 5, 2026.
  12. Medical review (expert opinion). Mayo Clinic. Sept. 2, 2026.

相关

Immunotherapy for breast cancer